Type I Interferon Signature In Sjogren’s Syndrome: Pathophysiological And Clinical Implications.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Marketos N, Cinoku I, Rapti A and Mavragani CP
Clinical and Experimental Rheumatology. 2019;37 Suppl 118:185-191.
Link to article: https://www.clinexprheumatol.org/abstract.asp?a=14416
Type I interferons (IFN) have long been recognised as mediators of innate immune defense mechanisms against viral threats. Robust evidence over the last 15 years revealed their significant role in the pathogenesis of systemic autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS). Despite the progress, methods of detection, initial triggers, biological functions and clinical associations in the setting of autoimmunity remain to be fully clarified. As therapeutic options for SS are currently limited, neutralising specific targets of the type I IFN pathway seems a promising option. In this review we summarise the current evidence regarding the role of type I IFN in SS.